Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Global stroke burden
- Thromboembolic occlusions and ischemic damage
- Possible interventions
- Consequences of low blood flow
- Recanalisation is associated with improvement
- Time is brain
- Where do thromboembolic occlusions originate?
- How can recanalisation be achieved?
- Pharmacological treatment
- Pharmacological treatment: alteplase
- Outcomes of alteplase treatment vs. placebo
- Importance of delay from stroke onset to treatment
- SITS-MOST
- Thrombolysis is safe and effective
- SITS-MOST univariate analysis results
- Door to needle time
- Treatment indications for intravenous rt-PA
- Comments on usual misunderstandings
- Treatment beyond European labelling
- Concern for haemorrhagic complications
- Risk factors for intracerebral haemorrhage (1)
- Risk factors for intracerebral haemorrhage (2)
- Recanalisation intervention beyond 3 hours
- Recanalisation strategies beyond i.v. thrombolysis
- HMCAS disappearance after i.v. thrombolysis
- HMCAS disappearance is important to outcome
- Thrombectomy using the MERCI device
- Example for the use of MERCI: background
- Example for the use of MERCI: the occlusion
- Example for the use of MERCI: the device location
- Example for the use of MERCI: recanalisation
- A clot on the MERCI device
- Combined iv thrombolysis- thrombectomy strategy
- Sonothrombolysis
- Possible hemorrhage and oedema complications
- Oedema complication
- Decompressive surgery
- Functional outcomes of decompressive surgery
- Risk reduction and odds ratio following surgery
- Eligibility criteria for the pooled analysis
- Exclusion criteria
- Thrombolysis for intracerebral haemorrhage
- New standards for organised stroke care
- Summary
- Thank you for your attention
Topics Covered
- Global stroke burden
- Neurological symptoms
- Where do thromboembolic occlusions originate?
- Recanalization
- Pharmacological treatment
- Clinical trials
- Treatment indications for intravenous rt-PA
- Common misunderstandings
- Treatment recommendations
- Haemorrhagic complications in routine clinical practice
- Multivariate analysis
- Risk factors
- Intravenous thrombolysis
- SITS
- Pooled analysis
- Thrombolysis and highly specialized interventions require new standards for organized stroke care
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wahlgren, N. (2008, October 27). The treatment of stroke: specific management - thrombolysis plus [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 23, 2024, from https://doi.org/10.69645/NAFG2782.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Nils Wahlgren has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.